Literature DB >> 26200283

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.

Akihiro Tamiya1, Shigeki Shimizu, Shinji Atagi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26200283     DOI： 10.1097/JTO.0000000000000575

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report.

Authors:  Yoko Yamamoto; Ken Kodama; Tomohiro Maniwa; Masashi Takeda; Hiroki Kishima
Journal:  Mol Clin Oncol       Date:  2016-04-26

Review 2.  Lung cancer in never smokers-the East Asian experience.

Authors:  Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2018-08

Review 3.  ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.

Authors:  Nobuaki Mamesaya; Kazuhisa Nakashima; Tateaki Naito; Takashi Nakajima; Masahiro Endo; Toshiaki Takahashi
Journal:  BMC Cancer       Date:  2017-07-06       Impact factor: 4.430

4.  Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Authors:  Junko Watanabe; Shinsaku Togo; Issei Sumiyoshi; Yukiko Namba; Kentaro Suina; Takafumi Mizuno; Kotaro Kadoya; Hiroaki Motomura; Moe Iwai; Tetsutaro Nagaoka; Shinichi Sasaki; Takuo Hayashi; Toshimasa Uekusa; Kanae Abe; Yasuo Urata; Fuminori Sakurai; Hiroyuki Mizuguchi; Shunsuke Kato; Kazuhisa Takahashi
Journal:  Oncotarget       Date:  2018-05-08

5.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Qiyi Meng; Yujie Dong; Hong Tao; Liang Shi; Li Tong; Junfang Tang; Shucai Zhang; Zhe Liu
Journal:  Thorac Cancer       Date:  2021-02-09       Impact factor: 3.500

6.  ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib.

Authors:  Ray Sagawa; Takehiko Ohba; Eisaku Ito; Susumu Isogai
Journal:  Case Rep Oncol Med       Date:  2018-03-18

7.  Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.

Authors:  Jun Shiihara; Fumiyoshi Ohyanagi; Hikari Amari; Minemichi Toda; Hiroki Tahara; Motoi Yuzawa; Yuki Maeda; Motoko Nomura; Yoshiko Mizushina; Yoshiaki Nagai; Hiromitsu Ohta; Yasuhiro Yamaguchi
Journal:  Thorac Cancer       Date:  2021-07-29       Impact factor: 3.500
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.